Spotlight on Oncology

Credits: 0.50 CME / CNE / CPE
Realizing Improved Outcomes in Advanced Prostate Cancer through Evolving Research and Emerging Treatment Paradigms: Challenges and Opportunities - Part 1
Daniel Petrylak, MD
Rush University Medical Center

Realizing Improved Outcomes in Advanced Prostate Cancer through Evolving Research and Emerging Treatment Paradigms: Challenges and Opportunities - Part 1

Start

Co-provided By

This activity is co-provided by Rush University and PleXus Communications.

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credits
0.5 Contact Hour(s)
Released: September 27, 2017
Expires: September 26, 2018
30 minutes to complete

Target Audience

Healthcare providers who are involved with the treatment of patients with prostate cancer

Learning Objectives

After completing this program, participants should be able to:

  1. Outline how a personalized approach to treatment, as it relates to the genetic landscape of prostate cancer, can impact patient prognosis and treatment selection
  2. Formulate appropriate care plans for patients with advanced prostate cancer based on individual patient disease characteristics, including considerations of the best clinically relevant strategies for combining and sequencing therapies
  3. Evaluate emerging treatment options for advanced prostate cancer based upon individual patient disease characteristics and treatment-related complications

Agenda

  • Current state of advanced prostate cancer in the US
  • Are we ready for biomarker driven treatment of advanced prostate cancer?
  • Management strategies for advanced prostate cancer
  • How do we sequence these agents?

Activity Description

The activity agenda has been designed to help clinicians understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient outcomes.

Faculty

Daniel P. Petrylak, MD
Professor of Medicine and Urology
Director, Genitourinary DART
Co-director, Signal Transduction Program
Smilow Cancer Center
Yale University School of Medicine
New Haven, CT

Disclosure
Research Grant: Celgene Corporation
Consultant: Celgene Corporation, Bristol-Myers Squibb (advisory board), Binding Site, Karyopharm Therapeutics, Janssen, Sanofi, and Takeda Pharmaceuticals U.S.A., Inc.


Conflict of Interest Policy/Disclosure Statement

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ANCC Credit Designation – Nurses
The maximum number of hours awarded for this CE activity is 0.5 contact hours.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this knowledge based CPE activity (0622-0000-17-038-H01-P) for 0.5 contact hours for pharmacists.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 75% or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by educational grants from Astellas Scientific and Medical Affairs, Inc. and Medivation Inc., a Pfizer Company, Bayer HealthCare Pharmaceuticals Inc., Clovis Oncology, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Sanofi Genzyme.

Disclaimer Statement / Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions About the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Oncology Presentations

0.25 CME
University of Nebraska Medical Center
The Next Steps in CAR T-Cell Therapy for the Treatment of Patients With Lymphoma

The Next Steps in CAR T-Cell Therapy for the Treatment of Patients With Lymphoma

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credits
Released: August 31, 2018
Expires: August 31, 2019
20 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Provider

This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Target Audience

The target audience for this activity is for community and academic medical oncologists, hematologists, advanced practitioners, and other clinicians who treat patients with lymphoma.

Learning Objectives

After completing this activity, participants should be better able to:

  • Review clinical trial data that led to approval of CAR T-cell–based therapies for the treatment of patients with lymphoma
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with lymphoma, including various combination strategies being examined
  • Develop strategies to mitigate adverse events often encountered with the use of CAR T-cell therapy, including cytokine release syndrome and neurotoxicity

Activity Description

Expert Insights is an interview involving 2 world renowned experts actively engaged in treatment of patients with lymphoma. This discussion features expert summary and interpretation of data presented during the 2018 Pan Pacific Lymphoma Conference in Hawaii, as well as provide guidance on the optimal use of current and emerging therapies.

Statement of Educational Need

CD19-targeted CAR T cells have emerged as a highly effective therapy in patients with NHL. However, multiple CAR T-cell technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with aggressive NHL need expert guidance to evaluate clinical data on CAR T-cell therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.

Faculty

Julie M. Vose, MD, MBA - Moderator
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Grants/Research Support: Acerta Pharma, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Kite Pharma, Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Novartis, Seattle Genetics, Inc.

Consultant Fees, Honorarium: AbbVie Inc., Epizyme, Inc., Karyopharm Therapeutics, Legend Pharmaceuticals, Novartis, Roche, Sandoz, Vaniam Group LLC


Sattva S. Neelapu, MD
Professor
Deputy Department Chair ad interim
Director of Laboratory and Translational Research
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Grants/Research Support, Advisor: Acerta Pharma, Bristol-Myers Squibb Company, Cellectis, Gilead, Karus, Kite, A Gilead Company, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Poseida

Consultant, Advisor: Celgene Corporation, Kite, A Gilead Company, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Novartis, Unum Therapeutics


Conflict of Interest Policy/Disclosure Statement

As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.

The following indicates the disclosure declaration information and the nature of those commercial relationships.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

Educational grant support provided by Celgene Corporation and Kite, A Gilead Company.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

University of Nebraska Medical Center, Center for Continuing Education
Brenda Ram, CMP, CHCP
bram@unmc.edu
402-559-9250

Bio Ascend
meetings@bioascend.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CNE / CPE
AXIS
Nursing and Pharmacy Provisions of Care for HR+/HER2− Advanced or Metastatic Breast Cancer: Spotlight on CDK 4/6 Inhibitors

Nursing and Pharmacy Provisions of Care for HR+/HER2− Advanced or Metastatic Breast Cancer: Spotlight on CDK 4/6 Inhibitors

Start

Activity Details

Free CPE/CNE
1.0 Contact Hour
Released: August 27, 2018
Expires: August 26, 2019
1 hour to complete

Provided by

This educational activity is provided by

Target Audience

This activity is intended for oncology nurses, advanced practitioners, pharmacists, pharmacy technicians, and other allied healthcare professionals involved in the team-based management of breast cancer.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Discuss the risks, benefits, and differentiation points among CDK 4/6 inhibitors for the treatment of HR-positive/HER2-negative advanced breast cancer with the healthcare team and patients.
  • Evaluate proper dosing and administration of oral CDK 4/6 inhibitors used in the treatment of HR-positive/HER2-negative advanced breast cancer.
  • Enhance patient education through shared decision-making strategies regarding therapy selection and the importance of oral therapy compliance to maximize therapeutic outcomes.
  • Educate patients on potential adverse events associated with CDK 4/6 inhibitors.
  • Develop strategies to anticipate, monitor and manage adverse events with oral CDK 4/6 inhibitors for the treatment of HR-positive/HER2-negative advanced breast cancer to maximize the benefits of these therapies.

Activity Description

The American Cancer Society estimated that in 2017 there were 255,180 new cases of breast cancer and 41,070 deaths due to breast cancer in the United States. Nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and, therefore, are not candidates for HER2-targeting therapies.

Significant advances include the development of agents that target critical pathways involved in resistance to endocrine therapy, such as cyclin-dependent kinase (CDK) 4/6 inhibitors. Differentiating among the agents that comprise this novel class will be essential practice skills that oncology advanced practitioners such as nurses and pharmacists will need to become more familiar with to advance patient care and support.

New oral agents are revolutionizing breast cancer care, and data show that patient adherence to the full duration of therapy is critical to realize the positive effects of these agents on tumor control and patient survival. Nurses and pharmacists can play a critical role in improving patient adherence to oral therapy, from treatment decision support and monitoring to management and patient counseling.

This activity will review these oral therapies, including risk and benefits, barriers to adherence, side effect monitoring and management and patient counseling on aspects such as dosing and safe handling of oral therapies. This will be coupled with education about shared decision-making strategies to achieve increased patient satisfaction, better adherence to treatment plans, greater treatment engagement, and better quality decision making.

Statement of Educational Need

The goal of this activity is to provide education about oral CDK 4 and 6 inhibitors for the treatment of HR+/HER2− advanced or metastatic breast cancer so nurses, pharmacists, and other healthcare professionals are able to educate, counsel, and support patients regarding benefits, dosing, adherence, and side effects of therapies to make informed decisions with the goal of improving patient outcomes.

Faculty

Pharmacy Co-Chairperson
Michael L. Brandt, PharmD, FASHP
Oncology Infusion Pharmacist
Cancer and Blood Specialties Center
Rockwood Clinic, MultiCare Health System
Spokane, Washington


Nurse Co-Chairperson
Jacquelyn H. Lauria, MS, RN, APN-C, AOCNP®
Advanced Practice Nurse
Rutgers Cancer Institute of New Jersey
Stacy Goldstein Breast Center
New Brunswick, New Jersey

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter

Reported Financial Relationship

Michael L. Brandt, PharmD, FASHP

Michael L. Brandt, PharmD, FASHP, has no real or apparent conflicts of interest to report

Jacquelyn H. Lauria, MS, RN, APN-C, AOCNP®

Jacquelyn H. Lauria, MS, RN, APN-C, AOCNP®, reported a financial interest/relationship or affiliation in the form of Serve(d) as a speaker or a member of a speakers bureau for: PUMA Biotechnology


The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Stephanie Sutphin, PharmD; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Credit Designation for Pharmacists/Pharmacy Technicians
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education credit (JA4008106-0000-18-039-H01-P and JA4008106-0000-18-039-H01-T).

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. Pharmacists – your record will be loaded to CPE Monitor.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
University of Nebraska Medical Center
The Time is Now: Focusing on New and Emerging Therapies for Improving Patient Outcomes in AML

The Time is Now: Focusing on New and Emerging Therapies for Improving Patient Outcomes in AML

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit
Released: August 20, 2018
Expires: August 20, 2019
45 minutes to complete

Accredited By

University of Nebraska Medical Center, Center for Continuing Education

Provided By


This activity is co-provided by University of Nebraska Medical Center, Center for Continuing Education and Integrity Continuing Education, Inc.

Target Audience

This program is intended for hematologists, medical oncologists, health system pharmacists, oncology nurses, nurse practitioners, physician assistants, and other healthcare providers involved in the care of patients with AML.

Learning Objectives

Upon completion of this educational activity, participants should be better able to:

  • Describe the pathophysiology of AML and identify potential therapeutic targets
  • Summarize current clinical trial evidence regarding the efficacy and safety of new and emerging therapies for AML
  • Outline an approach to AML treatment selection that is tailored based upon individual patient characteristics

Activity Description

Despite recent advances in understanding of the pathophysiology of AML and a corresponding expansion of targeted treatment modalities, the care of individuals with the disease remains a significant challenge in current clinical practice. The following program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote accurate disease classification and risk assessment, and personalized treatment for patients with AML, including older individuals and those with relapsing or refractory disease.

Faculty

Jorge E. Cortes, MD
Jorge E. Cortes, MD
Jane and John Justin Distinguished Chair in Leukemia Research
Section Chief of AML & CML
Deputy Chairman
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas


Richard M. Stone, MD
Richard M. Stone, MD
Professor of Medicine
Harvard Medical School
Chief of Staff
Director, Adult Acute Leukemia Program
Dana-Farber Cancer Institute
Boston, Massachusetts


Conflict of Interest Policy/Disclosure Statement

The University of Nebraska Medical Center, Center for Continuing Education and Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by The University of Nebraska Medical Center, Center for Continuing Education and Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Jorge E. Cortes, MD, has no real or apparent conflicts of interest to report.

Richard M. Stone, MD
Consultant: Abbvie, Agios, Amgen, Argenix, Arog, Astellas, Celator, Celgene, Cornerstone, Fujifilm, Janssen, Jazz, Juno, Karyopharm, Merck, Novartis, Ono, Orsenix, Otsuka, Pfizer
Research: Agios, Arog, Novartis
Board Member: Actinium
Steering Committee: Celgene

Patima Tanapat, PhD, has no real or apparent conflicts of interest to report.

Accreditation Statement for Physicians

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of August 20, 2018 through August 20, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The University of Nebraska Medical Center, Center for Continuing Education, Integrity Continuing Education, Inc. and Pfizer do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about this activity, please contact the University of Nebraska Medical Center, Center for Continuing Education at (402) 559-4152 or via email at conted@unmc.edu.

1.00 CME / CE
AKH Inc., Advancing Knowledge in Healthcare
A Systematic, Patient-Centered Approach to Managing Metastatic Gastric or GEJ Adenocarcinoma

A Systematic, Patient-Centered Approach to Managing Metastatic Gastric or GEJ Adenocarcinoma

Start

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 ANCC Contact Hour
Released: December 21, 2017
Expires: December 21, 2018
1 hour to complete

Media

Internet

Target Audience

Oncology clinicians including physicians, nurses, and PAs

Learning Objectives

  1. Summarize the pathogenesis and molecular pathways involved in the development and progression of gastric cancer
  2. Evaluate the safety, efficacy, and quality of data for available and emerging targeted therapies for locally advanced or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma
  3. Individualize and optimize treatment with sequencing and management of treatment-related adverse events for locally advanced or metastatic gastric and GEJ adenocarcinoma
  4. Engage patients with locally advanced or metastatic gastric and GEJ adenocarcinoma in their care by implementing effective shared decision making (SDM) strategies

Faculty

Jaffer A. Ajani, MD
Professor of Medicine, Department of Gastrointestinal Medical Oncology
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure Declaration

It is the policy of RMEI Medical Education, LLC and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH Inc. prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. planners and reviewers have no relevant financial relationships to disclose.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Jaffer A. Ajani, MD, has affiliations with Bristol-Myers Squibb, Celgene, Genentech, Insys, Lilly, and Medscape (Consulting Fees), and Bristol-Myers Squibb and Delta-Fly (Contracted Research). 

RMEI Medical Education, LLC

  • Tania Dickson, MD, has no affiliations with commercial interests to disclose.
  • Mindy Tanzola, PhD, has no affiliations with commercial interests to disclose.
  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Jessica Hatch has no affiliations with commercial interests to disclose.

AKH Inc. Staff and Planners
Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner: has no affiliations with commercial interests to disclose.
Patricia Brignoni, Sr. Project Manager: has no affiliations with commercial interests to disclose.

Continuing Education Information

CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Nurses
AKH Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is awarded 1.0 Contact Hour.

Jointly provided by RMEI Medical Education, LLC and AKH Inc., Advancing Knowledge in Healthcare.

How to Receive Credit

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through the participant's misunderstanding of the content.

Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions about the Activity

If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

0.50 CME / CNE
AXIS
Using “Rapid Progression” and Response Levels as Prognostic Markers in Selecting Optimal Second-Line Therapy for NSCLC

Using “Rapid Progression” and Response Levels as Prognostic Markers in Selecting Optimal Second-Line Therapy for NSCLC

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credits
0.5 Contact Hour(s)
Released: August 8, 2018
Expires: August 7, 2019
30 minutes to complete

Provided by

This educational activity is provided by

Target Audience

This activity is intended for medical oncologists, thoracic oncologists, pulmonologists, pathologists, oncology nurses, and other healthcare professionals involved in the treatment of NSCLC.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Analyze treatment options for patients with advanced NSCLC that does not have an actionable mutation target and has progressed on or after prior platinum-based therapy
  • Develop treatment plans for patients with advanced NSCLC without targetable activating mutations that has progressed on or after prior platinum-based therapy according to clinical practice guidelines
  • Select appropriate treatment for NSCLC without targetable activating mutations that has progressed rapidly on initial platinum-based therapy

Activity Description

Lung cancer continues to be the leading cause of cancer death in the United States, accounting for 27% of all cancer deaths in males and 25% in females. Non–small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancer cases. The prognosis of patients with NSCLC is poor; the 5-year overall survival (OS) rate is 5% for those with metastatic disease and 18% across all stages. Approximately 70% of patients with lung cancer have advanced or metastatic disease at initial diagnosis.

The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF mutations has led to an improvement in OS and progression-free survival by identifying subgroups of patients who benefit from targeted treatment. “Although recent advances have improved clinical outcomes for patients with tumors harboring targetable driver mutations, most NSCLC tumors lack these mutations, highlighting the need for novel therapeutic interventions… Patients with advanced NSCLC that is aggressive and rapidly progresses after first-line treatment have a poor prognosis and have been studied in several trials” (Reck et al, 2017).

This activity will review available treatment options, current guideline recommendations, and recent data about disease that has progressed rapidly on initial therapy to inform appropriate treatment selection.

Statement of Educational Need

The goal of this activity is to provide clinicians with the latest advances in the treatment of patients with advanced NSCLC without targetable activating mutations that has progressed on prior platinum-based therapy, including patients with disease that has progressed rapidly on initial therapy.

Faculty

Stephen V. Liu, MD
Associate Professor of Medicine
Lombardi Comprehensive Cancer Center
Georgetown University School of Medicine
Washington, DC


Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Stephen V. Liu, MD, reported a financial interest/relationship or affiliation in the form of Advisor/Consultant, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Co, Celgene Corp, Genentech/Roche, Ignyta, Lilly USA, Pfizer, Inc, Taiho Pharmaceutical Co, Ltd, Takeda Oncology; Contracted research, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Corvus Pharmaceuticals, Esanex Inc, Genentech, Inc, Ignyta, Lycera, MedImmune, Merck & Co, Inc, OncoMed Pharmaceuticals, Pfizer, Inc, Threshold Pharmaceuticals.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn Haas, PhD, RN, CNS, ANP-BC; and Stephanie Sutphin, PharmD,hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Designation of Credit

Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 100% and the post-activity evaluation, your certificate will be made available immediately.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME / CNE
AcademicCME
The Increasing Role of Biosimilars in Oncology

The Increasing Role of Biosimilars in Oncology

Start

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: June 15, 2018
Expires: September 17, 2019
1 hour to complete

Accredited By

Target Audience

Oncologists, primary care physicians, internists and advanced practice providers, including NPs and PAs, responsible for the diagnosis, treatment or management of patients with various cancers

Learning Objectives

  • Understand the fundamentals of biosimilars in oncology, including bioequivalence, totality of evidence, and interchangeability.
  • Evaluate the current clinical trial data of biosimilars for the treatment of various oncologic therapeutic areas.
  • Utilize the health care team and shared decision making to achieve improved outcomes in patients with various cancers.

Activity Description

This continuing education activity will focus on recent clinical trial data as well as therapeutic advances in the increasing role of biosimilars in oncology. The three expert faculty will review the fundamentals of biosimilars in oncology, including bioequivalence, totality of evidence, and interchangeability. A review of current clinical trial data of biosimilars for the treatment of various oncologic therapeutic areas will be presented. The faculty will discuss how to utilize the health care team and shared decision making to achieve improved outcomes in patients with various cancers. Upon completion of this activity, learners will gain knowledge on how to implement biosimilars in their treatment strategies for oncology patients.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding use of biosimilars and their role in modern day medicine.

Agenda

  1. A Scientific Overview of Biosimilars in Oncology
  2. A Clinical Analysis of Emerging Biosimilars in Oncology
  3. The Importance of Utilizing the Health Care Team and Shared Decision Making to Achieve Improved Outcomes

Faculty

Sanjiv S. Agarwala, MD
Chief of Medical Oncology and Hematology
St Luke's University Hospital and Health Network
Professor of Medicine
Temple University School of Medicine
Philadelphia, Pennsylvania


Amy Goodrich, RN, BSN, MSN, CRNP-AC
Research Associate
The Johns Hopkins School of Medicine
Nurse Practitioner
The Sidney Kimmel Cancer Center at Johns Hopkins
Baltimore, Maryland


Wasif M. Saif, MD, MBBS
Professor of Medicine
Director, GI Oncology Program
Program Leader, Experimental Therapeutics
Tufts Medical Center
Boston, Massachusetts


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

Sanjiv S. Agarwala, MD
Nothing to disclose.

Amy Goodrich, RN, BSN, MSN, CRNP-AC
Consultant/Advisor: Gilead
Speaker's Bureau: Gilead

Wasif M. Saif, MD, MBBS
Grant/Research Support: TAIHO ONCOLOGY, INC.
Speaker's Bureau: TAIHO ONCOLOGY, INC.

Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring; Chelsey Benedek; and Kim Cheramie, MSN, RN-BC, hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or Review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  • All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

Statement of Commercial Support

This activity has been supported by educational grants from Amgen Inc. and Boehringer Ingelheim.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Amgen Inc. and Boehringer Ingelheim do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE / CPE
AXIS
Managing Metastatic NSCLC: Strategies for Treatment Selection

Managing Metastatic NSCLC: Strategies for Treatment Selection

Start

Activity Details

Free CME/CPE/CNE
0.5 AMA PRA Category 1 Credits
0.5 Contact Hour(s)
Released: June 11, 2018
Expires: June 10, 2019
30 minutes to complete

Provided By

Target Audience

This activity is intended for community oncologists, nurses, pharmacists, and other healthcare professionals who manage NSCLC.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Summarize the indications, efficacy, and safety profiles of recently approved therapies for NSCLC, including EGFR and checkpoint inhibitors
  • Devise treatment selection and drug sequencing strategies that incorporate newer therapies for patients with metastatic NSCLC
  • Identify potential toxicities associated with therapies used for NSCLC

Activity Description

The goal of this activity is to provide expert perspective on frequently asked questions pertaining to the treatment of NSCLC so clinicians gain an enhanced understanding of this disease to make the best possible treatment choices for their patients. AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent grand rounds series on NSCLC.

Statement of Educational Need

The treatment of NSCLC has changed significantly as a result of the identification of clinically relevant biomarkers and the development of targeted therapies. Although patient outcomes have improved as a result of treatment advances, metastatic disease is still an important challenge. Knowledge and practice gaps can be seen in several aspects of the treatment of metastatic NSCLC, such as how to integrate new therapies into practice, manage toxicities associated with new therapies, and make best use of a shared decision-making approach to treatment.

Faculty

David S. Ettinger, MD, FACP, FCCP
Alex Grass Professor of Oncology
Professor of Medicine
Professor of Radiation Oncology and Molecular Radiation Sciences
The Johns Hopkins University School of Medicine
Baltimore, Maryland


Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

David S. Ettinger, MD, FACP, FCCP, serves(d) as an advisor/consultant for:
BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb Co; Eli Lilly and Co; Genentech, Inc; Golden Biotechnology Corporation; and Guardant Health, Inc.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda-Gracie-King, MS; Jocelyn Timko, BS; Kristen Baileys, RN, MSN, CRNP, OCN; Marilyn Haas, PhD, RN, CNS, ANP-BC; and Stephanie Sutphin, PharmD,hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Designation of Credit

Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Pharmacists
This knowledge-based activity is approved for 0.5 contact hours of continuing pharmacy education credit. JA4008106-0000-18-017-H01-P

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. Pharmacists – your record will be loaded to CPE Monitor.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE / CPE
Rush University Medical Center
Evolving Treatment Paradigms in Advanced Prostate Cancer: Individualizing Treatment Strategies Based on Advancing Clinical Data—Part Two

Evolving Treatment Paradigms in Advanced Prostate Cancer: Individualizing Treatment Strategies Based on Advancing Clinical Data—Part Two

Start

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: April 16, 2018
Expires: April 15, 2019
30 minutes to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

Healthcare providers who are involved in the treatment of patients with prostate cancer

Learning Objectives

After completing this program, participants should be able to:

  • Identify best practices for integrating current available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals.
  • Understand the molecular and biochemical underpinnings of mCRPC.
  • Describe molecular biomarkers that predict for response to novel targeted therapies.

Activity Description

The activity agenda has been designed to help clinicians understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient outcomes.

Faculty

Matthew B. Rettig, MD
Medical Oncologist
Ronald Reagan UCLA Medical Center and VA Greater Los Angeles Healthcare System
Los Angeles, CA

Dr. Rettig has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity:
Research Grant: Novartis
Member, Speakers Bureau: Janssen
Consultant: Janssen


Michaela Ryan, PhD
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Kimberly Lynch
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Beth-Anne M. Christopher MS, RN, CNL
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Conflict of Interest Policy/Disclosure Statement

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing education unit(s) in Pharmacy. UAN: JA0000275-0000-18-057-H01-P.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 75% or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by educational grants from Astellas Scientific and Medical Affairs, Inc. and Medivation, Inc., a Pfizer company, Clovis Oncology Inc., Janssen Biotech Inc. administered by Janssen Scientific Affairs, LLC, and Tolmar Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions about the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE / CPE
Rush University Medical Center
Evolving Treatment Paradigms in Advanced Prostate Cancer: Individualizing Treatment Strategies Based on Advancing Clinical Data—Part One

Evolving Treatment Paradigms in Advanced Prostate Cancer: Individualizing Treatment Strategies Based on Advancing Clinical Data—Part One

Start

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: April 16, 2018
Expires: April 15, 2019
30 minutes to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

Healthcare providers who are involved in the treatment of patients with prostate cancer

Learning Objectives

After completing this program, participants should be able to:

  • Identify best practices for integrating current available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals.
  • Understand the molecular and biochemical underpinnings of mCRPC.
  • Describe molecular biomarkers that predict for response to novel targeted therapies.

Activity Description

The activity agenda has been designed to help clinicians understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient outcomes.

Faculty

Matthew B. Rettig, MD
Medical Oncologist
Ronald Reagan UCLA Medical Center and VA Greater Los Angeles Healthcare System
Los Angeles, CA

Dr. Rettig has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity:
Research Grant: Novartis
Member, Speakers Bureau: Janssen
Consultant: Janssen


Michaela Ryan, PhD
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Kimberly Lynch
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Beth-Anne M. Christopher MS, RN, CNL
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Conflict of Interest Policy/Disclosure Statement

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing education unit(s) in Pharmacy. UAN: JA0000275-0000-18-053-H01-P.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 75% or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by educational grants from Astellas Scientific and Medical Affairs, Inc. and Medivation, Inc., a Pfizer company, Clovis Oncology Inc., Janssen Biotech Inc. administered by Janssen Scientific Affairs, LLC, and Tolmar Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions about the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME / CNE
AXIS
Oncology On-Que: Expert Answers to Common Questions for Optimizing Sarcoma Treatment

Oncology On-Que: Expert Answers to Common Questions for Optimizing Sarcoma Treatment

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hours for nurses
Released: March 6, 2018
Expires: March 5, 2019
15 minutes to complete

Provided By

Target Audience

This activity is intended for medical oncologists, surgical oncologists, radiation oncologists, orthopedic oncologists, pathologists, researchers, advanced practitioners, nurses, and other healthcare professionals who treat soft-tissue sarcomas.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Integrate dosing and administration recommendations for treatment with doxorubicin plus olaratumab
  • Use appropriate therapies for the treatment of soft-tissue sarcomas according to guideline recommendations
  • Identify appropriate treatments for uterine sarcoma
  • Recognize and manage adverse events in patients being treated for soft-tissue sarcomas
  • Assess advances in molecular testing in determining treatment approach
  • Evaluate emerging data for the use of immunotherapy in the treatment of soft-tissue sarcomas

Activity Description

Soft-tissue sarcomas (STS) comprise a heterogeneous group of rare diseases of mesenchymal origin. Its rarity (1% of adult malignancies) and diverse presentation (180+ classified subtypes) make STS a challenge to diagnose and treat. The standard of care involves a multimodal approach of radiation therapy, surgery, and chemotherapy; however, the 5-year survival rate for advanced/metastatic STS has remained approximately 16% for many years. Fortunately, there are multiple newly approved and emerging agents in late-stage clinical trials that may revolutionize the treatment of STS.

Because STS treatment is rapidly evolving, clinicians may not be up to date regarding the latest advances in the treatment of this disease, including available, newer, and emerging treatment options, making it challenging to provide state-of-the-art care to their patients.

AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. The topics outlined below feature a summary of the questions that were asked during a recent grand rounds series on sarcoma. This activity will review:

  • Dosing and administration of olaratumab
  • Treatments for uterine sarcoma
  • Adverse events and management
  • Choice of treatment/therapy
  • Optimal surveillance schedule for localized disease
  • The role of adjuvant chemotherapy
  • Molecular testing
  • The use of immunotherapy

Statement of Educational Need

The goal of this activity is to provide expert perspective on frequently asked questions pertaining to the treatment of sarcoma so clinicians gain an enhanced understanding of this disease to make the best possible treatment choices for their patients.

Faculty

Richard F. Riedel, MD
Associate Professor with Tenure
Division of Medical Oncology
Associate Director, Clinical & Translational Research Duke Sarcoma Program
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina


Conflict of Interest Policy/Disclosure Statement

The faculty, Richard F. Riedel, MD, reported a financial interest/relationship or affiliation in the form of Consultant/Advisory boards, Eisai Inc., EMD Serono, Ignyta, Janssen Biotech, Inc., Lilly USA, Loxo Oncology; Contracted research, Aadi Bioscience, Inc., AROG Pharmaceuticals, Inc., Bayer Pharmaceuticals Corporation, Eisai Inc., Ignyta, Immune Design, Karyopharm Therapeutics, Lilly USA, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Plexxikon, TRACON Pharmaceuticals, Inc.; Ownership, Biotech Prosthetics & Orthotics of Durham (Spouse), Limbguard, LLC (Spouse).

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Continuing Education Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Designation of Credit

Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.25 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other related information.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Pages